ALKS · Alkermes plc.
$41.00
+0.46 (+1.13%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$6.74B
Shares
167.76M
Volume · Oct 1
2.63M
Avg daily vol (3M)
1.8M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$40.54
Open$40.00
Day$39.99–41.41
52W close$27.20–55.22
Avg vol 30d2.0M
Short int15.2M · 9.0% float · 10.7d
Short vol43%
Last earningsJul 28, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 21, 2026
Est · unconfirmed
· in 3 wks
filed Jul 28, 2026
call held Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.67B
Trailing 12 months
Net income (TTM)
$66.12M
Trailing 12 months
Revenue growth YoY
+27.0%
Year over year
Operating margin
7.0%
Trailing 12 months
P / E (TTM)
106.6
Trailing earnings · reciprocal yield 0.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.0%
Year over year · more shares
Price change (1Y)
+35.1%
Trailing year
Short interest
9.0%
Latest settlement · 10.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
−14%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
48%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+22%
trailing
YTD return
+45%
this year
Relative strength
+9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $47 › 200d $39 — 50d above 200d
Institutional flow
Flat
1 of 426 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$2.2M over 90 days · 100% sells
Short interest
Rising
9.03% of float · ▲ +3.0% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
426 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
EPS growth
−34%
Y/Y
Free cash flow
$480.3M
Valuation
P/E 105.7
rich
Buyback
$172.3M
remaining
Balance sheet
$388.6M
net cash
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 28, 2026
2026
Vivitrol net sales
$460M – $480M
Q3
Total net sales from the four proprietary products
$390M – $410M
Cost of goods sold
$85M – $95M
Total revenues
$450M – $470M
generally similar to Q2 levels in the range of $390 to $410 mill
Net sales from the four proprietary products
$390M – $410M
third quarter
Costs
$85M – $95M
R&D expenses
$120M – $130M
SG&A expense
$215M – $225M
Adjusted EBITDA
$80M – $100M
for the year
EBITDA
$75M – $95M
Guided vs delivered
· last 5 settled
Total Revenues
2024 Expectations
guided $1.5B – $1.6B
$1.56B
In line
Projected Earnings Per Share
Year Ending December 31, 2024
guided $2.14
$2.17
Beat +1.4%
GAAP Earnings Per Share (Diluted)
Year Ending Dec. 31, 2023
guided $1.31 – $1.54
$2.10
Beat +47.4%
Total revenues
full year 2021
guided $1.15B – $1.19B
$1.17B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
−14%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
48%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $47 › 200d $39 — 50d above 200d
Institutional flow
Flat
1 of 426 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$2.2M over 90 days · 100% sells
Short interest
Rising
9.03% of float · ▲ +3.0% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
426 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $27
Now $41 · 48%
Range high $55
vs 200-day avg +4%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Alixorexton external R&D expenses | $28.8M | Three Months Ended June 30, 2026 filing | +21.0% |
|
|
|||
| ARISTADA and ARISTADA INITIO product sales, net | $96.7M | Three Months Ended June 30, 2026 filing | -4.5% |
|
|
|||
| Long-acting INVEGA products manufacturing and royalty revenues | $27.4M | Three Months Ended June 30, 2026 filing | — |
| LUMRYZ external R&D expenses | $4.7M | Three Months Ended June 30, 2026 filing | — |
|
|
|||
| LUMRYZ product sales, net | $96.6M | Three Months Ended June 30, 2026 filing | — |
|
|
|||
| LYBALVI product sales, net | $93.9M | Three Months Ended June 30, 2026 filing | — |
| Other manufacturing and royalty revenues | $26.3M | Three Months Ended June 30, 2026 filing | — |
| VIVITROL product sales, net | $124.5M | Three Months Ended June 30, 2026 filing | +2.3% |
|
|
|||
| VUMERITY manufacturing and royalty revenues | $30.6M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALKS
this stock
Alkermes plc.
|
$6.74B | +44.9% | -5.2% | 105.7 | 9.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.0% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.7% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALKS | -0.6% | -15.1% | +21.5% | +0.1% | +44.9% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -0.2% | -14.9% | +9.1% | -0.1% | +32.9% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$400.00M
Spent (derived)
$227.70M
Remaining
$172.30M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.